Short-term efficacy and safety of antithymocyte globulin treatment in elderly patients with acquired aplastic anaemia

Jennifer M-L. Tjon; Marco R. de Groot; Saskia M.A. Sypkens Smit; Liesbeth C. de Wreede; Tjeerd J.F. Snijders; Harry R. Koene; Ellen Meijer; Marc Raaijmakers; Michel Schaap; Reinier Raymakers; Sacha S. Zeerleder; Constantijn J.M. Halkes

doi:10.1111/bjh.14372

Short-term efficacy and safety of antithymocyte globulin treatment in elderly patients with acquired aplastic anaemia

Jennifer M-L. Tjon, Marco R. de Groot, Saskia M.A. Sypkens Smit, Liesbeth C. de Wreede, Tjeerd J.F. Snijders, Harry R. Koene, Ellen Meijer, Marc Raaijmakers, Michel Schaap, Reinier Raymakers, Sacha S. Zeerleder, Constantijn J.M. Halkes

Hematology

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

2 Citations (Scopus)

Abstract

Guidelines for the diagnosis and management of adult aplastic anaemia patients were published recently on behalf of the British Society for Standards in Haematology (Killick et al, 2016). The combination of horse-derived anti-thymocyte globulin (ATG) and ciclosporin (CSA) is considered to be the standard first-line immunosuppressive therapy (IST). However, in elderly patients (aged ≥ 60 years) it is advised to weigh-up the risks and benefits of this intensive treatment for each individual patient as older age is associated with an increased risk of acute and delayed toxicity of ATG-based treatment and the overall survival might be worse due to inferior tolerability.

We agree that it is important to look for the right balance between toxicity and efficacy of an intensive and potential hazardous treatment, especially in vulnerable patient groups such as patients aged ≥ 60 years. Unfortunately, data regarding the safety and toxicity of ATG-based treatment schedules in this age group are scarce. Current recommendations are partly based on data from the European Society for Blood and Marrow Transplantation (EBMT) registry. [...]

Original language	English
Pages (from-to)	459-462
Number of pages	4
Journal	British Journal of Haematology
Volume	180
Issue number	3
DOIs	https://doi.org/10.1111/bjh.14372
Publication status	Published - Feb 2018

Research programs

EMC OR-01

Access to Document

10.1111/bjh.14372

http://hdl.handle.net/1765/111111

Cite this

Tjon, J. M.-L., de Groot, M. R., Sypkens Smit, S. M. A., de Wreede, L. C., Snijders, T. J. F., Koene, H. R., Meijer, E., Raaijmakers, M., Schaap, M., Raymakers, R., Zeerleder, S. S., & Halkes, C. J. M. (2018). Short-term efficacy and safety of antithymocyte globulin treatment in elderly patients with acquired aplastic anaemia. British Journal of Haematology, 180(3), 459-462. https://doi.org/10.1111/bjh.14372

@article{84fd733584264e82bb8c18cd75a22c1f,

title = "Short-term efficacy and safety of antithymocyte globulin treatment in elderly patients with acquired aplastic anaemia",

abstract = "Guidelines for the diagnosis and management of adult aplastic anaemia patients were published recently on behalf of the British Society for Standards in Haematology (Killick et al, 2016). The combination of horse-derived anti-thymocyte globulin (ATG) and ciclosporin (CSA) is considered to be the standard first-line immunosuppressive therapy (IST). However, in elderly patients (aged ≥ 60 years) it is advised to weigh-up the risks and benefits of this intensive treatment for each individual patient as older age is associated with an increased risk of acute and delayed toxicity of ATG-based treatment and the overall survival might be worse due to inferior tolerability. We agree that it is important to look for the right balance between toxicity and efficacy of an intensive and potential hazardous treatment, especially in vulnerable patient groups such as patients aged ≥ 60 years. Unfortunately, data regarding the safety and toxicity of ATG-based treatment schedules in this age group are scarce. Current recommendations are partly based on data from the European Society for Blood and Marrow Transplantation (EBMT) registry. [...]",

author = "Tjon, \{Jennifer M-L.\} and \{de Groot\}, \{Marco R.\} and \{Sypkens Smit\}, \{Saskia M.A.\} and \{de Wreede\}, \{Liesbeth C.\} and Snijders, \{Tjeerd J.F.\} and Koene, \{Harry R.\} and Ellen Meijer and Marc Raaijmakers and Michel Schaap and Reinier Raymakers and Zeerleder, \{Sacha S.\} and Halkes, \{Constantijn J.M.\}",

year = "2018",

month = feb,

doi = "10.1111/bjh.14372",

language = "English",

volume = "180",

pages = "459--462",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley \& Sons Inc.",

number = "3",

}

Tjon, JM-L, de Groot, MR, Sypkens Smit, SMA, de Wreede, LC, Snijders, TJF, Koene, HR, Meijer, E, Raaijmakers, M, Schaap, M, Raymakers, R, Zeerleder, SS & Halkes, CJM 2018, 'Short-term efficacy and safety of antithymocyte globulin treatment in elderly patients with acquired aplastic anaemia', British Journal of Haematology, vol. 180, no. 3, pp. 459-462. https://doi.org/10.1111/bjh.14372

Short-term efficacy and safety of antithymocyte globulin treatment in elderly patients with acquired aplastic anaemia. / Tjon, Jennifer M-L.; de Groot, Marco R.; Sypkens Smit, Saskia M.A. et al.
In: British Journal of Haematology, Vol. 180, No. 3, 02.2018, p. 459-462.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Short-term efficacy and safety of antithymocyte globulin treatment in elderly patients with acquired aplastic anaemia

AU - Tjon, Jennifer M-L.

AU - de Groot, Marco R.

AU - Sypkens Smit, Saskia M.A.

AU - de Wreede, Liesbeth C.

AU - Snijders, Tjeerd J.F.

AU - Koene, Harry R.

AU - Meijer, Ellen

AU - Raaijmakers, Marc

AU - Schaap, Michel

AU - Raymakers, Reinier

AU - Zeerleder, Sacha S.

AU - Halkes, Constantijn J.M.

PY - 2018/2

Y1 - 2018/2

N2 - Guidelines for the diagnosis and management of adult aplastic anaemia patients were published recently on behalf of the British Society for Standards in Haematology (Killick et al, 2016). The combination of horse-derived anti-thymocyte globulin (ATG) and ciclosporin (CSA) is considered to be the standard first-line immunosuppressive therapy (IST). However, in elderly patients (aged ≥ 60 years) it is advised to weigh-up the risks and benefits of this intensive treatment for each individual patient as older age is associated with an increased risk of acute and delayed toxicity of ATG-based treatment and the overall survival might be worse due to inferior tolerability. We agree that it is important to look for the right balance between toxicity and efficacy of an intensive and potential hazardous treatment, especially in vulnerable patient groups such as patients aged ≥ 60 years. Unfortunately, data regarding the safety and toxicity of ATG-based treatment schedules in this age group are scarce. Current recommendations are partly based on data from the European Society for Blood and Marrow Transplantation (EBMT) registry. [...]

AB - Guidelines for the diagnosis and management of adult aplastic anaemia patients were published recently on behalf of the British Society for Standards in Haematology (Killick et al, 2016). The combination of horse-derived anti-thymocyte globulin (ATG) and ciclosporin (CSA) is considered to be the standard first-line immunosuppressive therapy (IST). However, in elderly patients (aged ≥ 60 years) it is advised to weigh-up the risks and benefits of this intensive treatment for each individual patient as older age is associated with an increased risk of acute and delayed toxicity of ATG-based treatment and the overall survival might be worse due to inferior tolerability. We agree that it is important to look for the right balance between toxicity and efficacy of an intensive and potential hazardous treatment, especially in vulnerable patient groups such as patients aged ≥ 60 years. Unfortunately, data regarding the safety and toxicity of ATG-based treatment schedules in this age group are scarce. Current recommendations are partly based on data from the European Society for Blood and Marrow Transplantation (EBMT) registry. [...]

U2 - 10.1111/bjh.14372

DO - 10.1111/bjh.14372

M3 - Comment/Letter to the editor

C2 - 27714765

SN - 0007-1048

VL - 180

SP - 459

EP - 462

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 3

ER -

Short-term efficacy and safety of antithymocyte globulin treatment in elderly patients with acquired aplastic anaemia

Abstract

Research programs

Access to Document

Fingerprint

Cite this